Evaluation of Completeness of Suspected Adverse Drug Reaction Reports Submitted to the Mexican National Pharmacovigilance CentreA Cross-Sectional Period-Prevalence Study

被引：0
|
作者：
Betsabé Sánchez-Sánchez
Marina Altagracia-Martínez
Jaime Kravzov-Jinich
Consuelo Moreno-Bonett
Everardo Vázquez-Moreno
Juan Manuel Martínez-Núñez
机构：
[1] Metropolitan Autonomous University-Xochimilco,Division of Biological and Health Sciences, Department of Biological Systems
[2] Pfizer Laboratory,undefined
来源：
Drug Safety | 2012年 / 35卷
关键词：
Adverse Drug Reaction; Pharmaceutical Industry; Pregabalin; Adverse Drug Reaction Report; Anatomical Therapeutic Chemical Classification;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: The Mexican National Centre of Pharmacovigilance (CNFV) receives suspected adverse drug reaction (ADR) reports from the pharmaceutical industry, Federal States Centre of Pharmacovigilance (CEFV) and Healthcare Institution Centres of Pharmacovigilance (CIFV). The completeness of these suspected ADR reports is particularly important for the proper evaluation of drug safety.
引用
收藏
页码：837 / 844
页数：7
相关论文
共 50 条
  • [31] A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China
    Wang, Ningsheng
    Chen, Yue
    Ren, Biqi
    Xiang, Yufang
    Zhao, Nan
    Zhan, Xianyan
    Feng, Bianling
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [32] Assessment of Knowledge, Attitude, and Practice in Adverse Drug Reaction Reporting of Healthcare Professionals in Vietnam: A Cross-Sectional Study
    Hai-Yen Nguyen-Thi
    Minh-Thu Do-Tran
    Thuyen Lu Ngoc
    Thuy-Tram Nguyen-Ngoc
    Nguyen Dang Tu Le
    HOSPITAL PHARMACY, 2022, 57 (03) : 392 - 401
  • [33] A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China
    Ningsheng Wang
    Yue Chen
    Biqi Ren
    Yufang Xiang
    Nan Zhao
    Xianyan Zhan
    Bianling Feng
    BMC Health Services Research, 22
  • [34] Prevalence of hospitalisation caused by adverse drug reactions at an internal medicine ward of a single centre in Japan: a cross-sectional study
    Komagamine, Junpei
    Kobayashi, Masaki
    BMJ OPEN, 2019, 9 (08):
  • [35] Evaluation of severe adverse cutaneous drug reactions in patients admitted to tertiary care center: A cross-sectional study
    Moshayedi, Mohammad Amin
    Asilian, Ali
    Mokhtari, Fatemeh
    HEALTH SCIENCE REPORTS, 2024, 7 (03)
  • [36] Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study
    Laroche, Marie-Laure
    Perault-Pochat, Marie-Christine
    Ingrand, Isabelle
    Merle, Louis
    Kreft-Jais, Carmen
    Castot-Villepelet, Anne
    Durrieu, Genevieve
    Gras, Valerie
    Guy, Claire
    Jean-Pastor, Marie-Josephe
    Jonville-Bera, Annie-Pierre
    Merlet-Chicoine, Isabelle
    Miremont-Salame, Ghada
    Nourhashemi, Fati
    Charmes, Jean-Pierre
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 (09) : 952 - 960
  • [37] A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Adverse Drug Reaction Reporting in the United Kingdom
    Klein, K.
    Hazell, L.
    Stolk, P.
    Shakir, S.
    DRUG SAFETY, 2018, 41 (11) : 1161 - 1162
  • [38] Mortality from adverse drug reaction-related hospitalizations in south-west Ethiopia: A cross-sectional study
    Angamo, M. T.
    Chalmers, L.
    Curtain, C. M.
    Yilma, D.
    Bereznicki, L.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2018, 43 (06) : 790 - 798
  • [39] Determining the frequency and preventability of adverse drug reaction-related admissions to an Irish University Hospital: a cross-sectional study
    Ahern, Fiona
    Sahm, Laura J.
    Lynch, Deirdre
    McCarthy, Suzanne
    EMERGENCY MEDICINE JOURNAL, 2014, 31 (01) : 24 - 28
  • [40] Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals
    Nibu Parameswaran Nair
    Leanne Chalmers
    Bonnie J. Bereznicki
    Colin Curtain
    Gregory M. Peterson
    Michael Connolly
    Luke R. Bereznicki
    Drug Safety, 2017, 40 : 597 - 606
12345